

**Doxylamine succinate and pyridoxine delayed release tablet (generic Diclegis)**  
**Effective 01/01/2026**

<b>Plan</b>	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Medical Benefit</b> <b>Pharmacy Benefit</b>	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
<b>Exceptions</b>	N/A		

**Overview**

Doxylamine with pyridoxine delayed-release tablets (generic Diclegis) are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

Bonjesta (doxylamine and pyridoxine delayed-release) tablets are nonformulary.

**Coverage Guidelines**

Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs

**OR**

Authorization may be granted for members when all the following criteria have been met:

1. Member has a diagnosis of nausea and vomiting associated with an active pregnancy
2. ONE of the following:
  - a. Member has had an inadequate response to combination therapy with pyridoxine and doxylamine taken concurrently
  - b. Provider submits clinical rationale why treatment with the concurrent use of pyridoxine and doxylamine is not appropriate.

**Limitations**

1. Initial approvals will be for a duration of 4 months.
2. Reauthorizations may be granted for up to an additional 6 months.
3. The following quantity limits apply:

Drug Name and Dosage Form	Quantity Limit
Doxylamine with pyridoxine 10mg/10mg	4 tablets per day

**References**

1. Doxylamine/pyridoxine [prescribing information]. Malvern, PA: Endo USA; April 2019
2. Fiaschi L, Nelson-Piercy C, Deb S, et al. Clinical management of nausea and vomiting in pregnancy and hyperemesis gravidarum across primary and secondary care: a population-based study. BJOG 2019; 126:1201

3. Koren G, Hankins GD, Clark S, et al. Effectiveness of doxylamine-pyridoxine for morning sickness. Am J Obstet Gynecol 2016; 214:664.

### **Review History**

2014 – Implementation

02/20/19 – Reviewed

04/27/15 – Reviewed

02/22/16 – Reviewed

02/27/17 – Reviewed

03/22/18 – Added Bonjesta

09/24/18 – Updated references

09/18/19 – Generic Diclegis

09/16/20 – Reviewed at P&T

11/16/2022 – Reviewed for Nov P&T. Separated out MH vs Comm/Exch. No clinical changes.

10/08/2025 – Reviewed and updated for September P&T. Removed Bonjesta from the policy as agent is moving to nonformulary status. Updated language for members who are new to the Plan. Effective 01/01/2026.

